Class of 2025
For exemplary research efforts leading to the development of chimeric antigen receptor-modified T-cell (CAR T-cell) therapy in pediatric patients, thereby revolutionizing personalized cancer treatment and leading to the FDA approval of tisagenlecleucel for B-cell acute lymphoblastic leukemia, the first CAR T-cell and gene therapy approved for use in patients.
*Full-length biography in development